Ergomed plc Board Change (6881M)
September 18 2019 - 2:01AM
UK Regulatory
TIDMERGO
RNS Number : 6881M
Ergomed plc
18 September 2019
PRESS RELEASE
Board Change
Guildford, UK - 18 September 2019: Ergomed plc, (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, today
announces that Dr Jan Petracek has stepped down as Ergomed's Chief
Operating Officer and Board Director, as well as CEO of
PrimeVigilance, on 17(th) September 2019.
Jan joined Ergomed as part of the acquisition of PharmInvent in
November 2016. PrimeVigilance has more than doubled revenues since
2016, including acquisitions, and now employs more than 500 staff.
Resuming his career focus on professional, educational and
scientific activities, Jan will remain with Ergomed in a consulting
capacity to ensure the smooth transition of leadership and to
continue his services to PrimeVigilance's clients as a Qualified
Person responsible for Pharmacovigilance (QPPV), auditor and
strategic advisor.
Jonathan West, currently Chief Business Officer of
PrimeVigilance, will take on the role of President of
PrimeVigilance. With 20 years' experience in pharmacovigilance
services, Jonathan first joined Ergomed in 2008 to establish
PrimeVigilance as a pharmacovigilance specialist services company.
He held the positions of Director of Business Operations and
Commercial Director & QPPV, and was appointed Chief Business
Officer in August 2018.
Dr Miroslav Reljanović, Executive Chairman of Ergomed,
commented: "Jan has made a huge contribution to the successful
growth of PrimeVigilance and Ergomed's pharmacovigilance offering.
The pharmacovigilance business is expected to show revenues
increasing 32% to GBP16.0 million in the first half of 2019 from
GBP12.1 million in the first half of 2018. We look forward to
continuing to benefit from Jan's expertise. We are delighted to
have Jonathan continuing in his role within Ergomed and taking up
the new position as President of PrimeVigilance to drive the
further development of the business."
Dr Jan Petracek said: "PrimeVigilance has grown very rapidly and
it has been a huge privilege to have been part of that journey. I
am grateful for the opportunity to continue to make a contribution,
and to assist in the smooth transition to support the company's
ongoing success."
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated
Adviser)
James Black (Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Sue Stuart ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical trials, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services business includes a full range of high-quality
contract research and trial management (CRO) services under the
Ergomed brand together with an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, and an internationally recognised specialist
expertise in orphan drug development, under the PSR brand. For
further information, visit: http://ergomedplc.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALFFEIAAIDLIA
(END) Dow Jones Newswires
September 18, 2019 02:01 ET (06:01 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024